Orris

Hypervitaminosis D

Reading File
Finding Sources
Finding Sources
Searching PubMed

"hypervitaminosis D" AND "vitamin D toxicity"

Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
I now have comprehensive data from Harrison's, Goodman & Gilman's, Fitzpatrick's, Katzung's, and Goldman-Cecil. Let me compile the full answer.

Hypervitaminosis D

Definition

Hypervitaminosis D (vitamin D intoxication/toxicity) is a state resulting from excessive accumulation of vitamin D or its metabolites, leading primarily to hypercalcemia and hypercalciuria with consequent end-organ damage.

Etiology / Causes

Exogenous (most common):
  • Chronic ingestion of high-dose vitamin D supplements (parent D compound, 25(OH)D3, or 1,25(OH)2D3)
  • Cod liver oil, herbal medicines containing vitamin D
  • Overtreatment of hypoparathyroidism
  • "Faddist" use of excessive doses - Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 208
Endogenous (abnormal metabolism):
  • Granulomatous diseases: sarcoidosis, tuberculosis, histoplasmosis, coccidiomycosis, leprosy, HIV - unregulated extrarenal 1α-hydroxylase activity in macrophages produces excess 1,25(OH)2D
  • Lymphoma
  • Williams syndrome - endogenous overproduction of 25(OH)D3
  • CYP24A1 (24-hydroxylase) mutations - impaired catabolism of 1,25(OH)2D3
  • Infantile hypercalcemia - Harrison's Principles of Internal Medicine 22E (2025), p. 1332

Dose Threshold

The toxic dose varies considerably between individuals:
  • Significant hypercalcemia generally requires >10,000 IU/day chronically in otherwise healthy individuals - Harrison's 22E, p. 1331
  • As a rough approximation, continued daily ingestion of 50,000 IU/day or more may result in poisoning - Goodman & Gilman's, p. 210
  • The tolerable upper intake level is 4,000 IU/day (100 µg/day) for persons >9 years - Yamada's Textbook of Gastroenterology
  • Reported cases of toxicity had 25(OH)D levels of 710-1587 nmol/L

Pathophysiology

The primary mechanism is hypercalcemia driven by:
  1. Increased intestinal calcium absorption - vitamin D (primarily via elevated 25(OH)D) acts on intestinal receptors to enhance calcium and phosphate absorption
  2. Increased bone resorption - high levels mobilize calcium from bone
  3. Enhanced renal calcium reabsorption - both calcium and phosphate reabsorption are increased, potentially leading to calciphylaxis - Quick Compendium of Clinical Pathology 5th ed., p. 1076
The key mediator in exogenous toxicity is 25(OH)D (not necessarily 1,25(OH)2D which may not be frankly elevated), because:
  • Production of 25(OH)D is less tightly regulated than 1,25(OH)2D
  • 25(OH)D has intrinsic, though low-level, biologic activity at intestinal and bone receptors
  • Concentrations of 25(OH)D can rise several-fold with excess intake - Harrison's 22E, p. 1333
In granulomatous disease, by contrast, the culprit is excess 1,25(OH)2D produced by macrophage 1α-hydroxylase that lacks the normal negative feedback from calcium/phosphate. TNF and other inflammatory cytokines upregulate both the vitamin D receptor and 1α-hydroxylase in granuloma macrophages.

Clinical Features

Symptoms of hypercalcemia (initial):
SystemManifestations
GeneralWeakness, lethargy, fatigue
CNSHeadache, confusion, depression
GINausea, vomiting, anorexia, constipation
RenalPolyuria, polydipsia (nephrogenic DI), nephrolithiasis
CardiovascularHypertension, shortened QT interval
Signs of chronic/severe toxicity:
  • Metastatic calcification - deposits in soft tissues, vessel walls, and organs
  • Nephrocalcinosis and irreversible renal failure
  • Nephrolithiasis
  • Subcutaneous calcification, predominantly periarticular - Fitzpatrick's Dermatology, p. 1585
  • Band keratopathy (corneal calcification)
  • Bone pain and fractures

Diagnosis

  • Serum 25(OH)D > 100 ng/mL (250 nmol/L) - confirms vitamin D intoxication; this is the diagnostic marker - Harrison's 22E, p. 1335
  • Serum calcium: elevated (hypercalcemia)
  • Serum phosphate: elevated (hyperphosphatemia) - renal reabsorption enhanced
  • PTH: suppressed (low) - the negative feedback from hypercalcemia suppresses PTH
  • 1,25(OH)2D: may be normal or even low in exogenous toxicity (but elevated in granulomatous causes)
  • Urinary calcium: increased (hypercalciuria)

Differential Diagnosis

Other causes of hypercalcemia to distinguish from:
  • Primary hyperparathyroidism (PTH is elevated, not suppressed)
  • Malignancy-associated hypercalcemia (PTHrP elevated)
  • Sarcoidosis (1,25(OH)2D elevated, not 25(OH)D primarily)
  • Milk-alkali syndrome
  • Thiazide diuretics, lithium
  • Thyrotoxicosis, pheochromocytoma

Treatment

1. Discontinue vitamin D supplementation - the first and most important step
2. Hydration and dietary calcium restriction
  • Restrict calcium intake
  • Ensure adequate hydration
  • Usually sufficient for mild hypercalcemia
3. Glucocorticoids - the cornerstone of pharmacotherapy for vitamin D-mediated hypercalcemia:
  • Prednisone 40-100 mg/day (or equivalent) orally - Harrison's 22E, p. 1335
  • Intravenous hydrocortisone 200-400 mg/day for severe cases - Harrison's 22E, p. 488
  • Works by: antagonizing vitamin D-stimulated intestinal calcium absorption, decreasing 1,25(OH)2D production, and stimulating renal calcium excretion - Katzung's Pharmacology
  • Usually returns serum calcium to normal within several days
4. For severe/acute hypercalcemia:
  • IV normal saline (aggressive hydration)
  • Loop diuretics (furosemide) after adequate hydration
  • Bisphosphonates (inhibit bone resorption) for refractory cases
  • Calcitonin for rapid short-term lowering
5. For CYP24A1 mutations:
  • Avoidance of sunlight and vitamin D intake
  • Reduce calcium intake
  • Fluconazole or ketoconazole (CYP27B1 inhibitors) - Harrison's 22E
Important caveat: Because vitamin D is fat-soluble, 25(OH)D stores in adipose tissue can be substantial. Vitamin D intoxication may persist for weeks to months even after discontinuation, requiring prolonged treatment. - Harrison's 22E, p. 1335

Key Distinguishing Points: Exogenous vs. Endogenous

FeatureExogenous toxicityGranulomatous (endogenous)
Elevated metabolite25(OH)D1,25(OH)2D
PTHSuppressedSuppressed
1α-hydroxylase sourceRenal (regulated)Macrophages (unregulated)
Responds to steroidsYesYes
CauseSupplement overuseSarcoid, TB, lymphoma, etc.
Sources:
  • Harrison's Principles of Internal Medicine 22E (2025), pp. 1331-1335
  • Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 208-210
  • Fitzpatrick's Dermatology, p. 1585
  • Katzung's Basic and Clinical Pharmacology 16e, p. 567
  • Goldman-Cecil Medicine, p. 1723-1728
  • Quick Compendium of Clinical Pathology 5e, p. 1072-1076
  • Yamada's Textbook of Gastroenterology 7e, p. 833-836

Give every answer form Harrison

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
This is a shared conversation. Sign in to Orris to start your own chat.